Treatment patterns, overall survival (OS), and disease-free survival (DFS) in early stage non-small cell lung cancer (NSCLC) following complete resection

被引：1
|
作者：
West, H. [1 ]
Hu, X. [2 ]
Burke, T. [2 ]
Walker, M. S. [3 ]
Wang, Y. [3 ]
Samkari, A. [2 ]
机构：
[1] City Hope Comprehens Canc Ctr, Duarte, CA USA
[2] Merck & Co Inc, Kenilworth, NJ USA
[3] ConcertAI, Memphis, TN USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.02.099
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
89P
引用
收藏
页码：S74 / S74
页数：1
相关论文
共 50 条
  • [1] Disease-free survival (DFS) as a predictor of overall survival (OS) in completely resected early stage non-small cell lung cancer (NSCLC)
    West, H.
    Hu, X.
    Burke, T.
    Walker, M. S.
    Wang, Y.
    Samkari, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S74 - S75
  • [2] A retrospective analysis of treatment patterns, overall survival, and real-world disease-free survival in early-stage non-small cell lung cancer following complete resection
    Hu, Xiaohan
    Chirovsky, Diana
    Walker, Mark S.
    Wang, Yuexi
    Kaushiva, Alpana
    Tepsick, Jon
    Samkari, Ayman
    BMC PULMONARY MEDICINE, 2024, 24 (01):
  • [3] Polymorphisms in ERCC2 and overall survival (OS) in early stage non-small cell lung cancer (NSCLC).
    Suk, R
    Park, S
    Liu, G
    Cogan-Drew, T
    Zhou, W
    Su, L
    Lynch, T
    Wain, J
    Christiani, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 842S - 842S
  • [4] Real-world Disease-Free Survival as a Predictor of Overall Survival in Resected Early-Stage Non-Small Cell Lung Cancer
    West, H.
    Hu, X.
    Chirovsky, D.
    Song, Y.
    Zhang, S.
    Gao, C.
    Carley, C.
    Lerner, A.
    Signorovitch, J.
    Samkari, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S219 - S220
  • [5] Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP).
    Sweeney, Christopher
    Xie, Wanling
    Regan, Meredith M.
    Nakabayashi, Mari
    Buyse, Marc E.
    Clarke, Noel W.
    Collette, Laurence
    Dignam, James J.
    Fizazi, Karim
    Habibian, Muriel
    Halabi, Susan
    Kantoff, Philip W.
    Parulekar, Wendy R.
    Sandler, Howard M.
    Sartor, Oliver
    Soule, Howard R.
    Sydes, Matthew Robert
    Tombal, Bertrand F.
    Williams, Scott G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Adjuvant chemotherapy improves overall and disease-free survival in non-small cell lung cancer (NSCLC): results of the IALT trial
    Le Chevalier, T
    Kozlowski, M
    Pignon, JP
    Bergman, B
    Orlowski, T
    Pirker, R
    Le Pechoux, C
    Tarayre, M
    Dunant, A
    LUNG CANCER, 2004, 46 : S13 - S13
  • [7] Association between hospital volume, treatment patterns, and overall survival (OS) of patients with stage 3A non-small cell lung cancer (NSCLC).
    Tella, Harsha
    Kommalapati, Anuhya
    Ganti, Apar Kishor
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Interleukin polymorphisms associated with overall survival, disease-free survival, and recurrence in non-small cell lung cancer patients
    Woods, Nicholas T.
    Monteiro, Alvaro N.
    Thompson, Zachary J.
    Amankwah, Ernest K.
    Naas, Nina
    Haura, Eric B.
    Beg, Amer A.
    Schabath, Matthew B.
    MOLECULAR CARCINOGENESIS, 2015, 54 : E172 - E184
  • [9] A Nomogram to Predict Disease-Free Survival After Curative Resection of Non-Small Cell Lung Cancer
    Zhai, X.
    Wang, Z.
    Zheng, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S653 - S653
  • [10] Overall Survival (OS) of Pathological N2 Non-Small Cell Lung Cancer (NSCLC) After Surgical Resection
    Bourdages-Pageau, E.
    Vieira, A.
    Labbe, C.
    Figueroa, P. Ugalde
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2233 - S2233
12345